News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
49.75
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
918
Open
49.75
Bid (Size)
49.95 (1)
Ask (Size)
50.86 (1)
Prev. Close
49.75
Today's Range
49.75 - 49.75
52wk Range
20.84 - 50.07
Shares Outstanding
115,926,629
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Key Takeaways From Corcept Therapeutics Analyst Ratings
October 18, 2024
Via
Benzinga
Is NASDAQ:CORT suited for high growth investing?
October 17, 2024
Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing?
Via
Chartmill
Performance
YTD
+105.92%
+105.92%
1 Month
+17.75%
+17.75%
3 Month
+43.91%
+43.91%
6 Month
+123.09%
+123.09%
1 Year
+82.57%
+82.57%
More News
Read More
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
October 14, 2024
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
October 08, 2024
Via
Chartmill
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
September 30, 2024
Via
Benzinga
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
September 18, 2024
Via
Benzinga
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
September 09, 2024
Via
Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
August 16, 2024
Via
Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
August 05, 2024
Via
Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
September 17, 2024
Via
Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
August 27, 2024
Via
Chartmill
Unveiling 8 Analyst Insights On Corcept Therapeutics
July 30, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
July 29, 2024
Via
InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
6 Analysts Have This To Say About Corcept Therapeutics
June 17, 2024
Via
Benzinga
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
July 15, 2024
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
July 15, 2024
Via
Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
Via
InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
June 26, 2024
Via
InvestorPlace
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
June 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
June 24, 2024
Via
Chartmill
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
June 14, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close